1. Hodi, FS, O’Day, SJ, McDermott, DF,  et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
Google Scholar | Crossref | Medline | ISI2. Robert, C, Thomas, L, Bondarenko, I,  et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–2526.
Google Scholar | Crossref | Medline | ISI3. Weber, JS, D’Angelo, SP, Minor, D,  et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384.
Google Scholar | Crossref | Medline | ISI4. Larkin, J, Chiarion-Sileni, V, Gonzalez, R,  et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.
Google Scholar | Crossref | Medline | ISI5. Robert, C, Schachter, J, Long, GV,  et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–2532.
Google Scholar | Crossref | Medline | ISI6. Fecher, LA, Agarwala, SS, Hodi, FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733–743.
Google Scholar | Crossref | Medline | ISI7. Weber, JS, Kähler, KC, Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691–2697.
Google Scholar | Crossref | Medline | ISI8. Kreamer, KM . Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol 2014; 5: 418–431.
Google Scholar | Medline9. Postow, MA, Sidlow, R, Hellmann, MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158–168.
Google Scholar | Crossref | Medline10. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
Google Scholar | Crossref | Medline | ISI11. Brahmer, JR, Lacchetti, C, Schneider, BJ,  et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018; 36: 1714–1768.
Google Scholar | Crossref | Medline12. Salem, JE, Allenbach, Y, Vozy, A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019; 380: 2377–2379.
Google Scholar | Crossref | Medline